# Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

> **NCT03513562** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Ibrutinib Resistance

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03513562
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03513562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03513562, "Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03513562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*